Navigation Links
MIMETAS Appoints BHI Entrepreneur-in-Residence Todd Chappell as General Manager, U.S. Affairs
Date:1/6/2014

ROCKVILLE, Md. and BALTIMORE, Jan. 6, 2014 /PRNewswire/ -- BioHealth Innovation, Inc. (BHI) and MIMETAS announced today that Todd Chappell, MBA, an Entrepreneur-in-Residence for BHI, has been named General Manager, U.S. Affairs for MIMETAS. A Netherlands-based company, MIMETAS is establishing its offices within BHI's headquarters in Rockville. MIMETAS and BHI created a U.S. subsidiary of MIMETAS to access the clinical, regulatory and scientific resources available in Central Maryland and to access the U.S. marketplace, the largest life sciences market in the world.

"We're very pleased to add Todd to the MIMETAS team," said Jos Joore, Ph.D., Chief Business Officer of MIMETAS. "Todd couples a vast experience in business creation with a profound understanding of biology and disease mechanisms. Most importantly, Todd shares our sense of urgency around enabling better medical treatment by using more predictive cell culture models."

Previously, Mr. Chappell was the Vice President of Operations for Shape Pharmaceuticals, a portfolio company of HealthCare Ventures, LLC, where he oversaw all day-to-day operations involved in the development of a novel HDAC inhibitor for Cutaneous-T-Cell-Lymphoma. Prior to that, he was at CombinatoRx Inc. for eight years and served as Director of New Products. Mr. Chappell will be combining his role at MIMETAS with his existing EIR position at BHI.

"A U.S. market presence is of crucial importance to further expand the MIMETAS business model," said Mr. Chappell. "The United States leads the way in driving enhanced models for development of new drugs and the MIMETAS Organ-on-a-Chip platform is an important option for early-stage drug development and later-stage therapy selection."

MIMETAS' OrganoPlates™ contain 96 3D cell cultures that are each individually perfused with medium. The platform allows for arbitrary co-culture complexity without usage of artificial membranes and mimics gradients of signaling molecules similar to the human body. Moreover the microtiter plate platform is fully compatible to industrial screening and readout equipment.  

"We identified MIMETAS as a high potential, fast-growing company," said Rich Bendis, President & CEO of BHI. "The presence of MIMETAS in the state of Maryland is therefore mutually beneficial: it provides MIMETAS with access to top U.S. institutions such as Johns Hopkins University, University of Maryland, NIH, and FDA while the presence of MIMETAS here will help generate high-tech jobs in the state of Maryland."

MIMETAS currently is looking to fill a business development role. This new position will establish and manage the U.S. subsidiary in collaboration with BHI. Further information is available on the BHI website.

About MIMETAS
MIMETAS develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. MIMETAS' products are designed to offer increased predictive value as compared to laboratory animals and conventional cell culture models. The MIMETAS OrganoPlate™ platform allows 3D cell culture with continuous perfusion, membrane-free co-culture, boundary and gradient formation. In close collaboration with its customers, MIMETAS develops and validates customized disease, toxicology and transport models. Ultimately, MIMETAS will make its technology available for personalized therapy selection. Visit www.mimetas.com for more information.

About BioHealth Innovation, Inc.
BioHealth Innovation, Inc., is a regional innovation intermediary focused on commercializing market-relevant bio-health innovations and increasing access to early-stage funding in Maryland. Learn more at www.biohealthinnovation.org.


'/>"/>
SOURCE BioHealth Innovation, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ajinomoto Althea Inc. Appoints J. David Enloe Jr. as President and Chief Executive Officer
2. Concord Medical Announces Results of 2013 Annual General Meeting; Appoints New Board Members
3. ViaCyte Appoints Mark Foletta, former CFO of Amylin, to its Board of Directors
4. BioMed Realty Trust Appoints Dr. William R. Brody, President Of The Salk Institute, To Its Board Of Directors
5. Vermillion Appoints Marian E. Sacco as SVP of Sales and Marketing and Chief Commercial Officer
6. Relmada Therapeutics Inc. Appoints Douglas J. Beck As Chief Financial Officer
7. Hologic Appoints Stephen P. MacMillan President and Chief Executive Officer
8. Nutranomics Appoints MD and PhD Microbiologist as Supply Chain Manager
9. Savara Pharmaceuticals Appoints Two New Members to Its Board of Directors
10. Sysmex America Appoints Alex Garini Chief Financial Officer
11. Anavex Appoints Alzheimers Industry Leader to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... “America On The Brink”: the Christian history of the United States ... creation of published author, William Nowers. Captain Nowers and his wife, Millie, have ... thirty years in the Navy. Following his career as a naval aviator and ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
Breaking Medicine News(10 mins):